<DOC>
	<DOCNO>NCT00327470</DOCNO>
	<brief_summary>The purpose study determine benefit treat subject neovascular age-related macular degeneration ( AMD ) early stage choroidal neovascularization ( CNV ) compare establish CNV . Additionally , study would like determine efficacy Macugen preserve visual function subject CNV secondary neovascular AMD .</brief_summary>
	<brief_title>An Open Label Trial Investigate Macugen Preservation Visual Function Subjects With Neovascular AMD</brief_title>
	<detailed_description>A decision make sponsor ( 08 May 2009 ) terminate study early ; study achieve primary objective prior termination . This study terminate due safety reason .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Evidence neovascular AMD least one eye . In subject bilateral neovascular AMD , one eye would eligible enrollment Baseline visual acuity great equal 20/320 , good 25 ETDRS letter study eye Previous treatment CNV secondary AMD , include prior PDT verteporfin , thermal laser photocoagulation , external beam radiation transpupillary thermotherapy study eye Subjects subfoveal fibrosis/ scar atrophy represent &gt; 25 % total lesion size</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>neovascular age relate macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>